BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rigor J, Pinto SA, Martins-mendes D. Porphyrias: A clinically based approach. European Journal of Internal Medicine 2019;67:24-9. [DOI: 10.1016/j.ejim.2019.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Esteve-Valverde E, Tapiz-Reula A, Ruiz D, Alijotas-Reig J. Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. Rheumatol Int 2020;40:777-83. [PMID: 31865445 DOI: 10.1007/s00296-019-04500-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Oliveira R, Ramalho Rocha F, Teodoro T, Oliveira Santos M. Acute non-traumatic tetraparesis - Differential diagnosis. J Clin Neurosci 2021;87:116-24. [PMID: 33863518 DOI: 10.1016/j.jocn.2021.02.024] [Reference Citation Analysis]
3 Zhao L, Wang X, Zhang X, Liu X, Ma N, Zhang Y, Zhang S. Therapeutic strategies for acute intermittent porphyria. Intractable Rare Dis Res 2020;9:205-16. [PMID: 33139979 DOI: 10.5582/irdr.2020.03089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Elsaid MI, Li Y, Catalano C, Minacapelli CD, Gupta K, Rustgi VK. Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States. Pharmacoecon Open 2021;5:89-100. [PMID: 32897528 DOI: 10.1007/s41669-020-00229-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Reimann JDR, Moynihan SP, Horn TD. Assessment of Clinical and Laboratory Use of the Cutaneous Direct Immunofluorescence Assay. JAMA Dermatol 2021;157:1343-8. [PMID: 34613346 DOI: 10.1001/jamadermatol.2021.3892] [Reference Citation Analysis]